Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Research

| More

Maintain ADD on Torrent Pharma - Stable performance, Resilient outlook - HDFC Securities

Posted On: 2020-05-27 20:51:56


Ms. Bansi Desai, Institutional Research Analyst, HDFC Securities.

Torrent Pharma (Q4FY20): Stable performance, Resilient outlook. Maintain ADD
(TP Rs 2,605 , CMP Rs 2,582 , MCap Rs 437 bn)

Torrent's Q4 Adj. PAT came ahead of expectations driven by higher margins and lower tax. Torrent's EBITDA margin (27.3% in FY20, +100bps YoY) are best among peers and are further set to expand led by improving MR productivity and price led growth in India business. We expect FCF generation of ~Rs 47bn over next two years to lower net debt/EBITDA to ~0.3x by FY22e from ~1.8x in FY20. We increase our EPS estimates by 4-7% for FY21/22e on account of resilient margins aided by cost control efforts. We revise our TP to Rs2,605 based on 16x EV/EBIDTA based on FY22 estimates.

In line revenues, margins beat: Revenues at Rs19.5bn were led by strong growth in India (+11% YoY, +15% YoY adjusted for Covid) and RoW markets (+15% YoY). EBIDTA margin (28.2%, +234bps YoY, +174bps QoQ) was aided by productivity improvement, Unichem synergies and focus on cost control. Reported PAT was boosted by one time tax benefit of Rs530mn.

India business to outperform peerset: India growth in Q4 was driven by market share expansion and strong momentum in new launches (Ticagrelor, Vildagliptin and Remogliflozin).We expect India business (chronic focused) to grow ahead of Industry driven by price led growth & ramp up in new launches.

Other markets: US business maintained its quarterly run rate of USD50mn despite lack of new launches in FY20. We expect growth to remain tepid in FY21, however, resolution of plant can lead to higher approvals (48 pending ANDA) and improve growth visibility. Brazil market grew at 11% YoY (cc terms) in Q4 led by market share gains and new launches. We believe Torrent's strong presence in chronic segment (CNS, Cardiac, Diabetes) will lead to continued outperformance in this market.

Key call takeaways: a) Dahej - completed CAPA, invited FDA for desktop audit, Indrad - plan to complete CAPA by Q2FY21, Levittown - production will commence from Q3FY21; b) Debt repayment - Rs10bn in FY21, Capex - Rs2-2.5bn in FY21/22; c) India growth - price led growth should continue; volume for acute biz will be impacted; d) Working capital increased by Rs3-3.5bn on Mar 20 (lockdown led), has normalized now.

Maintain Add, risks: We increase our EPS estimates by 4-7% for FY21/22 and revise our TP to Rs2,605 (from Rs2,405 earlier) based on 16x FY22 EV/EBIDTA. Key risks: Slower growth in Indian formulation market; higher price erosion in US generic market; delay in resolution of OAI at Dahej and WL at Indrad facilities.

Shares of TORRENT PHARMACEUTICALS LTD. was last trading in BSE at Rs.2403.55 as compared to the previous close of Rs. 2581.25. The total number of shares traded during the day was 63430 in over 7515 trades.

The stock hit an intraday high of Rs. 2618 and intraday low of 2375. The net turnover during the day was Rs. 156627310.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Real Estate (Sector Update) - Greenshoots visible - HDFC Securities

Cement (Sector Update) - Prices, retail sales hold up despite COVID - HDFC Securities

TCI Express - Branch economics, cost levers as margin tailwinds - ICICI Securities

Mishra Dhatu Nigam - Space order inflow may slow down in FY21 - ICICI Securities

Century Plyboards - Compelling BUY; top pick in building materials - ICICI Securities

Building material - Sector Update - ICICI Securities

ISGEC Heavy Engineering - On a strong footing despite macro headwinds - ICICI Securities

Telecom - Growth breaks due to Covid-19 crisis - ICICI Securities

Pfizer Ltd - Company Update - ICICI Securities

Petronet LNG - Quant Pick - ICICI Securities

Earnings Wrap Q4FY20: Quarter end lockdown takes toll, one-offs rule Q4FY20

Autos & Transportation Sector Update Report - Focus on '3Cs' - HDFC Securities

Banking Sector Credit Trends - Weakness building - HDFC Securities

India Equity Strategy Report - Back to pre-covid levels - HDFC Securities

Strategy: Cyclicals to lead earnings recovery over FY20-22 - ICICI Securities

JK Cement - Ripe for re-rating - ICICI Securities

Phillips Carbon Black - Company Update - ICICI Securities

Information Technology - Q1FY21 Result Preview - ICICI Securities

Motherson Sumi Systems Ltd - Company Update - ICICI Securities

HDFC Ltd - Quant Pick - ICICI Securities

Auto Sales Data for June 2020 - Angel Broking

FMCG - Sector Review 4QFY20 - Disruption visible, growth divergence increases - HDFC Securities

Maintain ADD on ONGC - Impairment loss drags earnings - HDFC Securities

Maintain BUY on Ahluwalia Contracts - Looking ahead - HDFC Securities

RIL-Intel Deal - Angel Broking

Strategy: 'Out of turn' change in NIFTY50 due to Vedanta delisting - ICICI Securities

Time Technoplast - Q4FY20 Result Update - ICICI Securities

Monthly Auto Volumes - July 2020 - ICICI Securities

Oil & Natural Gas Corporation - Q4FY20 Result Update - ICICI Securities

Minda Industries - Q4 FY20 Result Update - ICICI Securities

Auto Sales - June 2020 - Acuité Ratings & Research

Bharat Electronics - Q4FY20 Result Update - ICICI Securities

Petronet LNG - Q4FY20 Result Update - ICICI Securities

Tata Steel - Q4FY20 Result Update - ICICI Securities

Phoenix Mills - Q4FY20 Result Update - ICICI Securities

Jun-20 Volumes expectations: Sales to rise over 2x from May-20 levels for Hero, Maruti - HDFC Securities

Maintain REDUCE on RBL Bank - Risks more evident - HDFC Securities

Maintain ADD on Subros - Expect market share gains to continue - HDFC Securities

Maintain ADD on Petronet LNG - One offs in opex drag profitability - HDFC Securities

Siyaram Silk Mills - Company Update - ICICI Securities

Vardhman Textiles - Company Update - ICICI Securities

Bharat Forge - Q4FY20 Result Update - ICICI Securities

CESC - Q4FY20 Result Update - ICICI Securities

Star Cement - Company Update - ICICI Securities

BUY on GIC Reinsurance - Arduous Road Ahead - HDFC Securities

ADD on Oil India - Excess provisions drag EBITDA - HDFC Securities

Maintain BUY on Sobha - Well placed for recovery - HDFC Securities

Maintain REDUCE on Emami - Miss on all fronts - HDFC Securities

BUY on Galaxy Surfactants - Higher per unit EBITDA leads profitability - ICICI Securities

Maintain BUY on J. Kumar Infraprojects - Migration headwinds - HDFC Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019